Abstract
Glioblastoma has long proven to be a challenging disease in regard to chemotherapeutic delivery as it grows within a privileged site protected by the selective blood-brain barrier. For many years biodegradable polymers were investigated as potential drug delivery systems. However, polymer technology in the drug delivery setting only truly advanced after the polyanhydrides were tested and demonstrated to be safe and effective platforms for controlled delivery of hydrolytically unstable chemotherapeutics. An in-depth series of biochemical and preclinical studies laid the foundation for the translation of these findings into clinical use for the treatment of glioblastoma with carmustine. This chapter provides the historical perspective of the carmustine implants through preclinical safety, intracranial distribution, and efficacy studies to clinical trials in recurrent and newly diagnosed glioblastoma and subsequent FDA approval of this chemotherapeutic delivery concept. Moreover, these studies provide a successful framework on which to expand in this new era of targeted and controlled drug delivery.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ostrom QT et al (2014) The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology 16(7):896–913. https://doi.org/10.1093/neuonc/nou087
Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330
Furnari FB et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21(21):2683–2710. https://doi.org/10.1101/gad.1596707
Weller M et al (2013) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14(9):e370–e379. https://doi.org/10.1016/S1470-2045(13)70168-2
Liu A et al (2016) Genetics and epigenetics of glioblastoma: applications and overall incidence of IDH1 mutation. Front Oncol 6:16. https://doi.org/10.3389/fonc.2016.00016
Gruber ML, Hochberg FH (1990) Systematic evaluation of primary brain tumors. J Nucl Med 31(6):969–971
Groothuis DR et al (1982) Permeability of different experimental brain tumor models to horseradish peroxidase. J Neuropathol Exp Neurol 41(2):164–185
Neuwelt EA et al (1982) Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci U S A 79(14):4420–4423
Banks WA (2009) Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 9(Suppl 1):S3. https://doi.org/10.1186/1471-2377-9-S1-S3
Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1(1):55–68
Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3–14. https://doi.org/10.1602/neurorx.2.1.3
Smith QR et al (1988) Kinetics and distribution volumes for tracers of different sizes in the brain plasma space. Brain Res 462(1):1–9
Pollay M, Roberts PA (1980) Blood-brain barrier: a definition of normal and altered function. Neurosurgery 6(6):675–685
Avsenik J, Bisdas S, Popovic KS (2015) Blood-brain barrier permeability imaging using perfusion computed tomography. Radiol Oncol 49(2):107–114. https://doi.org/10.2478/raon-2014-0029
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507. https://doi.org/10.1056/NEJMra0708126
Chaichana KL, Pinheiro L, Brem H (2015) Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas. Ther Deliv 6(3):353–369. https://doi.org/10.4155/tde.14.114
Heller J, Baker R (1980) Theory and practice of controlled drug delivery from bioerodible polymers. In: Controlled release of bioactive materials. Elsevier, Amsterdam, pp 1–17
Pitt G et al (1981) Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (ε-caprolactone), and their copolymers in vivo. Biomaterials 2(4):215–220
Conix A (1958) Aromatic polyanhydrides, a new class of high melting fiber-forming polymers. J Polym Sci A Polym Chem 29(120):343–353
Rosen HB et al (1983) Bioerodible polyanhydrides for controlled drug delivery. Biomaterials 4(2):131–133
Chasin M et al (1990) Polyanhydrides as drug delivery systems. Biodegrad Poly Drug Deliv Syst 45:43–70
Domb A, Langer R (1987) Polyanhydrides. I. Preparation of high molecular weight polyanhydrides. J Polym Sci A Polym Chem 25(12):3373–3386
Leong K, Brott B, Langer R (1985) Bioerodible polyanhydrides as drug-carrier matrices. I: characterization, degradation, and release characteristics. J Biomed Mater Res A 19(8):941–955
Leong K et al (1986) Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J Biomed Mater Res A 20(1):51–64
Mathiowitz E, Langer R (1987) Polyanhydride microspheres as drug carriers I. hot-melt microencapsulation. J Control Release 5(1):13–22
Langer R, Brem H, Tapper D (1981) Biocompatibility of polymeric delivery systems for macromolecules. J Biomed Mater Res A 15(2):267–277
Tamargo RJ et al (1989) Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res A 23(2):253–266
Brem H et al (1989) Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel Cancer Ther 5(2):55–65
Steen RG et al (1988) In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1, 3-bis (2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology. Cancer Res 48(3):676–681
Grant Steen R et al (1989) In vivo31P nuclear magnetic resonance spectroscopy of rat 9l gliosarcoma treated with BCNU: dose response of spectral changes. Magn Reson Med 11(2):258–266
Yang MB, Tamargo RJ, Brem H (1989) Controlled delivery of 1, 3-bis (2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 49(18):5103–5107
Domb A et al (1991) Controlled delivery of water soluble and hydrolytically unstable anti-cancer drugs for polymeric implants. Polym Prepr 32(2):219–220
Grossman SA et al (1992) The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 76(4):640–647
Tamargo RJ et al (1993) Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 53(2):329–333
Brem H et al (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74(3):441–446. https://doi.org/10.3171/jns.1991.74.3.0441
Brem H et al (1994) Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80(2):283–290
Wu MP et al (1994) In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy. J Biomed Mater Res A 28(3):387–395
Fung LK et al (1996) Chemotherapeutic drugs released from polymers: distribution of 1, 3-bis (2-chloroethyl)-l-nitrosourea in the rat brain. Pharm Res 13(5):671–682
Fung LK et al (1998) Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58(4):672–684
Dang W, Daviau T, Brem H (1996) Morphological characterization of polyanhydride biodegradable implant Gliadel® during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res 13(5):683–691
Sipos EP et al (1997) Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 39(5):383–389
Ewend M et al. (2019) Local delivery of BCNU from biodegradable polymer is superior to radiation therapy in treating intracranial melanoma metastases. In: SURGICAL FORUM-CHICAGO-. pp. 564–565
Ewend MG et al (1996) Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 56(22):5217–5223
Brem H (1990) Polymers to treat brain tumours. Biomaterials 11(9):699–701
Brem H, Langer R (1996) Polymer-based drug delivery to the brain. Sci Med 3:52–61
Brem H et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345(8956):1008–1012
Drapeau A, Fortin D (2015) Chemotherapy delivery strategies to the central nervous system: neither optional nor superfluous. Curr Cancer Drug Targets 15(9):752–768
Brem H et al (1995) The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neuro-Oncol 26(2):111–123
Valtonen S et al (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41(1):44–49
Westphal M et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5(2):79–88. https://doi.org/10.1093/neuonc/5.2.79
Menei P et al (2010) Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17(7):1740–1746. https://doi.org/10.1245/s10434-010-1081-5
Hart MG et al (2011) Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev 3:CD007294. https://doi.org/10.1002/14651858.CD007294.pub2
Aoki T et al (2014) A multicenter phase I/II study of the BCNU implant (Gliadel((R)) wafer) for Japanese patients with malignant gliomas. Neurol Med Chir (Tokyo) 54(4):290–301
McGirt MJ et al (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110(3):583–588. https://doi.org/10.3171/2008.5.17557
McGirt MJ, Brem H (2010) Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol 17(7):1729–1731. https://doi.org/10.1245/s10434-010-1092-2
Gururangan S et al (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology 3(4):246–250. https://doi.org/10.1093/neuonc/3.4.246
Salmaggi A et al (2013) Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J Neurosurg 118(4):821–829. https://doi.org/10.3171/2012.12.JNS111893
Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neuro-Oncol 88(3):353–357. https://doi.org/10.1007/s11060-008-9576-7
Bock HC et al (2010) First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 33(4):441–449. https://doi.org/10.1007/s10143-010-0280-7
Salmaggi A et al (2011) Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel. Neurol Sci 32(Suppl 2):S241–S245. https://doi.org/10.1007/s10072-011-0797-8
Miglierini P et al (2012) Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin Neurol Neurosurg 114(9):1222–1225. https://doi.org/10.1016/j.clineuro.2012.02.056
Ashby LS, Smith KA, Stea B (2016) Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World J Surg Oncol 14(1):225. https://doi.org/10.1186/s12957-016-0975-5
Chaichana KL et al (2011) The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol Res 33(7):759–764. https://doi.org/10.1179/1743132811Y.0000000006
Milojkovic Kerklaan B et al (2016) Strategies to target drugs to gliomas and CNS metastases of solid tumors. J Neurol 263(3):428–440. https://doi.org/10.1007/s00415-015-7919-9
Ewend MG et al (1998) Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 43(5):1185–1193
Ewend MG et al (2007) Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 13(12):3637–3641. https://doi.org/10.1158/1078-0432.CCR-06-2095
Mu F et al (2015) Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis. J Clin Neurosci 22(3):561–565. https://doi.org/10.1016/j.jocn.2014.08.020
Ene CI et al (2016) Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors. Surg Neurol Int 7(Suppl 11):S295–S299. https://doi.org/10.4103/2152-7806.181987
Brem S et al (2013) Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer 119(21):3830–3838. https://doi.org/10.1002/cncr.28307
Abel TJ et al (2013) Gliadel for brain metastasis. Surg Neurol Int 4(Suppl 4):S289–S293. https://doi.org/10.4103/2152-7806.111305
Olivi A et al (2003) Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 21(9):1845–1849. https://doi.org/10.1200/JCO.2003.09.041
Xing WK et al (2015) The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis. Drug Des Devel Ther 9:3341–3348. https://doi.org/10.2147/DDDT.S85943
Chowdhary SA, Ryken T, Newton HB (2015) Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neuro-Oncol 122(2):367–382. https://doi.org/10.1007/s11060-015-1724-2
Attenello FJ et al (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15(10):2887–2893. https://doi.org/10.1245/s10434-008-0048-2
Perry J et al (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 14(5):189–194
Zhang YD et al (2014) Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review. Turk Neurosurg 24(5):639–645. https://doi.org/10.5137/1019-5149.JTN.8878-13.1
Kleinberg L (2012) Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide. Core Evid 7:115–130. https://doi.org/10.2147/CE.S23244
Woodworth GF et al (2014) Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 4:126. https://doi.org/10.3389/fonc.2014.00126
Olivi A et al (1996) Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother Pharmacol 39(1-2):90–96
Brem S et al (2007) Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 60(5):643–650. https://doi.org/10.1007/s00280-006-0407-2
Mangraviti A et al (2017) HIF-1alpha- targeting Acriflavine provides long term survival and radiological tumor response in brain cancer therapy. Sci Rep 7(1):14978. https://doi.org/10.1038/s41598-017-14990-w
Lin SH, Kleinberg LR (2008) Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8(3):343–359. https://doi.org/10.1586/14737140.8.3.343
Mathios D et al (2016) Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med 8(370):370ra180. https://doi.org/10.1126/scitranslmed.aag2942
Blanchette M, Fortin D (2011) Blood-brain barrier disruption in the treatment of brain tumors. In: The Blood-Brain and Other Neural Barriers. Springer, New York, pp 447–463
Jackson S et al (2016) The effect of regadenoson-induced transient disruption of the blood–brain barrier on temozolomide delivery to normal rat brain. J Neuro-Oncol 126(3):433–439
Marty B et al (2012) Dynamic study of blood–brain barrier closure after its disruption using ultrasound: a quantitative analysis. J Cereb Blood Flow Metab 32(10):1948–1958
Jackson S et al (2018) The effect of an adenosine A 2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15(1):2
Chakraborty S et al (2016) Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. J Neuro-Oncol 128(3):405–415
Carpentier A et al (2016) Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med 8(343):343re342
Raghavan R et al (2006) Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 20(4):E12. https://doi.org/10.3171/foc.2006.20.4.7
Mangraviti A, Tyler B, Brem H (2015) Interstitial chemotherapy for malignant glioma: future prospects in the era of multimodal therapy. Surg Neurol Int 6(Suppl 1):S78–S84. https://doi.org/10.4103/2152-7806.151345
Richards Grayson AC et al (2003) Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater 2(11):767–772
Kim GY et al (2007) Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. J Control Release 123(2):172–178. https://doi.org/10.1016/j.jconrel.2007.08.003
Masi BC et al (2012) Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. Biomaterials 33(23):5768–5775. https://doi.org/10.1016/j.biomaterials.2012.04.048
Farra R et al (2012) First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med 4(122):122ra121. https://doi.org/10.1126/scitranslmed.3003276
Zhang Z et al (2018) Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations. Drug Deliv 25(1):166–177
Zhang Y-H et al (2011) Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats. Med Oncol 28(3):901–906
Zhu T et al (2014) BCNU/PLGA microspheres: a promising strategy for the treatment of gliomas in mice. Chin J Cancer Res 26(1):81
Allhenn D et al (2013) A “drug cocktail” delivered by microspheres for the local treatment of rat glioblastoma. J Microencapsul 30(7):667–673
Zhang D et al (2012) The effect of temozolomide/poly (lactide-co-glycolide)(PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior. Int J Mol Sci 13(1):1109–1125
Ozeki T et al (2012) Combination therapy of surgical tumor resection with implantation of a hydrogel containing camptothecin-loaded poly (lactic-co-glycolic acid) microspheres in a C6 rat glioma model. Biol Pharm Bull 35(4):545–550
Mangraviti A et al (2015) Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. ACS Nano 9(2):1236–1249
Menei P et al (2005) Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 56(2):242–248
Wei X et al (2015) Liposome-based glioma targeted drug delivery enabled by stable peptide ligands. J Control Release 218:13–21
P-j Y et al (2014) OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma. Mol Cancer 13(1):191
Chastagner P et al (2015) Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma. Cancer Chemother Pharmacol 76(2):425–432
Clarke JL et al (2017) A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol 79(3):603–610
Zhao M et al (2018) Targeted therapy of intracranial glioma model mice with curcumin nanoliposomes. Int J Nanomedicine 13:1601
Chen X et al (2016) Synergistic combination of doxorubicin and paclitaxel delivered by blood brain barrier and glioma cells dual targeting liposomes for chemotherapy of brain glioma. Curr Pharm Biotechnol 17(7):636–650
Voges J et al (2003) Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54(4):479–487
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Casaos, J., Gorelick, N., Tyler, B. (2021). Neurosurgical Implant-Based Strategy for Brain Cancer Therapy. In: Agrahari, V., Kim, A., Agrahari, V. (eds) Nanotherapy for Brain Tumor Drug Delivery. Neuromethods, vol 163. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1052-7_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1052-7_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1051-0
Online ISBN: 978-1-0716-1052-7
eBook Packages: Springer Protocols